Phase II randomized double blinded, placebo controlled trial to evaluate the safety and tolerability of an investigational drug in the treatment of mild hepatic encephalopathy.
The purpose of this study is to obtain information on the safety and the effectiveness of an experimental drug compared to placebo when it is used to treat mild encephalopathy.
You may be eligible to participate in this study if you:
You will be excluded from this study:
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.